PMID: 1203627Nov 1, 1975Paper

Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration

British Journal of Pharmacology
A R Green, M B Youdim

Abstract

1 The effect of various doses of tranylcypromine on the degree of inhibition of rat brain monoamine oxidase (MAO) using 5-hydroxytryptamine (5-HT), dopamine and phenylethylamine as substrates has been examined 120 min after injection of the inhibitor. The concentration of brain 5-HT was also examined both after tranylcypromine alone and also when L-tryptophan (100 mg/kg) had been given 30 min after the tranylcypromine. 2 All doses of tranylcypromine greater than 2.5 mg/kg totally inhibited MAO oxidation of 5-HT, phenylethylamine and dopamine as measured in vitro and produced a similar rise of brain 5-HT in vivo. When tryptophan was also given, there was a further rise of brain 5-HT, which was comparable after all doses of tranylcypromine above 2.5 mg/kg and the characteristic syndrome of hyperactivity made is appearance. 3 Clorgyline (a "Type A" MAO inhibitor), in doses up to 10 mg/kg, did not totally inhibit MAO activity towards phenylethylamine although it did inhibit 5-HT oxidation by 100%. Deprenil (a "Type B" MAO inhibitor) at doses up to 10 mg/kg did not fully inhibit 5-HT oxidation although phenylethylamine oxidation was inhibited almost completely. Administration of either compound alone did not produce as great an accu...Continue Reading

References

Jul 1, 1975·British Journal of Pharmacology·M B Youdim
May 1, 1973·British Medical Bulletin·M B Youdim
Jan 1, 1974·International Pharmacopsychiatry·M Sandler, M B Youdim
Sep 1, 1969·Biochemical Pharmacology·J Southgate, G G Collins
Jul 1, 1968·Biochemical Pharmacology·J P Johnston
Jan 1, 1968·Advances in Pharmacology·N H Neff, T N Tozer
May 1, 1965·Biochemical Pharmacology·S H SnyderM Zweig
Dec 1, 1964·International Journal of Neuropharmacology·C C CHANG

❮ Previous
Next ❯

Citations

Jan 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·K T Finnegan
Jan 1, 1980·Psychopharmacology·T G ReigleJ J Schildkraut
Mar 1, 1980·Naunyn-Schmiedeberg's Archives of Pharmacology·R OrtmannA Delini-Stula
Sep 1, 1987·Cellular and Molecular Neurobiology·R T CouttsT W Hall
Jan 1, 1993·Journal of Neural Transmission. General Section·M B Youdim, P Riederer
Feb 15, 1988·Experientia·M B Youdim
Jan 1, 1997·European Archives of Psychiatry and Clinical Neuroscience·S E HiltonH J Möller
Dec 10, 1985·European Journal of Pharmacology·M B Youdim, R Ashkenazi
Mar 12, 1985·European Journal of Pharmacology·W A WolfD M Kuhn
Aug 2, 1990·European Journal of Pharmacology·K T FinneganJ W Langston
Aug 1, 1981·Pharmacology, Biochemistry, and Behavior·J D Pollock, N Rowland
Nov 1, 1985·Pharmacology, Biochemistry, and Behavior·D L Sparks, N S Buckholtz
May 1, 1986·Pharmacology, Biochemistry, and Behavior·T NabeshimaT Kameyama
Jun 1, 1980·Journal of Affective Disorders·J Mendlewicz, M B Youdim
Feb 1, 1994·Progress in Neurobiology·M D BerryI A Paterson
Jun 5, 1992·European Journal of Pharmacology·M GerlachM B Youdim
Jun 1, 1997·Comparative Biochemistry and Physiology. Part C, Pharmacology, Toxicology & Endocrinology·R RadojićićV Davidović
Jan 26, 2000·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·J C AlvarezO Spreux-Varoquaux
Mar 9, 2000·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·H Silver, M B Youdim
Nov 1, 1979·The Journal of Pharmacy and Pharmacology·P E KeaneM S Benedetti
Apr 15, 1999·Annual Review of Neuroscience·J C ShihM J Ridd
May 29, 2014·The Journal of Clinical Investigation·Jason Boyang WuLeland W K Chung
Jul 1, 1994·Mayo Clinic Proceedings·L CarrH Lehnert
Apr 7, 2007·Neuropharmacology·Anne-Sophie VillégierFrances M Leslie
Jan 13, 2006·British Journal of Pharmacology·Moussa B H Youdim, Y S Bakhle

❮ Previous
Next ❯

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.